Evaluation of Analgesia Nociception Index (ANI) During Propofol/Remifentanil and Sevoflurane/Remifentanil Anesthesia

Detection of Nociceptive Stimulation by Analgesia Nociception Index (ANI) During Anesthesia With Propofol or Sevoflurane and Varying Remifentanil Concentrations.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01522508

Enrollment

Registered

2012-01-31

Start date

2011-06-30

Completion date

2012-10-31

Last updated

2012-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anaesthesia

Keywords

Analgesia, Anesthetics, Diagnostic Techniques and Procedures

Brief summary

The aim of this prospective randomized study was to evaluate the ability of the new Analgesia Nociception Index ANI, derived by heart rate variability, to detect painful stimulation during either propofol or sevoflurane anesthesia and changing remifentanil concentrations.

Detailed description

Monitoring Antinociception during general anesthesia is still a big challenge in the field and has not become clinical routine yet. Recently, for the Surgical Pleth Index SPI a benefit for the patient in terms of reduction of remifentanil use, less unwanted effects and shorter recovery from anesthesia was reported. However, there are new variables like the ANI that are developed to measure antinociception during anesthesia. In the present study the investigators want to evaluate, whether ANI detects a painful tetanic stimulus during general anesthesia using propofol or sevoflurane and different concentrations of remifentanil.

Interventions

PROCEDUREtetanic stimulation

as test stimulus a painful tetanic stimulation is used

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* age between 18- 65 years, * ASA physical status I or II, * elective surgery in general anesthesia planned, * written informed consent

Exclusion criteria

* pregnancy, * history of cardiac arrhythmia, * presents of any neuromuscular or neurologic disease, * use of CNS-active medication or abuse of alcohol/illicit drugs -

Countries

Germany

Contacts

Primary ContactMatthias Gruenewald, MD

matthias.gruenewald@uksh.de+49 431 597 2991

Backup ContactBerthold Bein, MD, PhD, DEAA

berthold.bein@uksh.de+49 431 597 2991

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026